Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bioventus (BVS) Short-term Investments (2021 - 2022)

Bioventus' Short-term Investments history spans 2 years, with the latest figure at $23000.0 for Q4 2022.

  • For Q4 2022, Short-term Investments fell 99.56% year-over-year to $23000.0; the TTM value through Dec 2022 reached $23000.0, down 99.56%, while the annual FY2022 figure was $23000.0, 99.56% down from the prior year.
  • Short-term Investments reached $23000.0 in Q4 2022 per BVS's latest filing, roughly flat from $23000.0 in the prior quarter.
  • In the past five years, Short-term Investments ranged from a high of $5.3 million in Q4 2021 to a low of $23000.0 in Q4 2022.